Company intelligence / Profile preview

OWL Metabolomics

Mungia, Basque Country, Spain

Ownership: Private
Development stage: Other

Overview

OWL Metabolomics (One Way Liver) markets CE-marked serum-based, metabolomics diagnostic tests (OWLiver®, OWL Liver Care) for NAFLD and NASH, commercially available in Spain and used by academic and clinical centers for non-invasive liver disease diagnosis and patient monitoring[3][1].

Therapeutic areas: Gastroenterology
Modalities: Diagnostic testMetabolomics service (not a therapeutic modality but a platform for biomarker discovery; does not develop therapeutics themselves)
Industry: Metabolite Diagnostics

Partnerships

NuSirt Biopharma (collaboration for companion diagnostics in NAFLD/NASH trials)

Beyond the preview

Go deeper on OWL Metabolomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OWL Metabolomics.

Explore the full profile